We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Novartis has announced that a phase III QUARTZ study of its investigational inhaled combination treatment, QMF149, has met primary and key secondary endpoints in patients with inadequately controlled asthma.